EcoDrugPlus

Ribosyldihydronicotinamide Dehydrogenase [Quinone]-Like

Ensembl ID : ENSORLG00000017876
Gene Symbol: LOC111946266
4 Cross references
185 Possible Orthologues:

Selectin E

Ensembl ID : ENSORLG00000016725
Gene Symbol: SELE
2 Cross references
183 Possible Orthologues:

Selectin P

Ensembl ID : ENSORLG00000016698
Gene Symbol: SELP
1 Cross references
49 Possible Orthologues:

Serine/threonine-Protein Kinase D3

Ensembl ID : ENSORLG00000018118
Gene Symbol: LOC101171628
3 Cross references
201 Possible Orthologues:

Serine/threonine-Protein Phosphatase 2b Catalytic Subunit

Ensembl ID : ENSORLG00000005223
Gene Symbol: LOC101169815
3 Cross references
233 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSORLG00000009062
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
320 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSORLG00000011902
Gene Symbol: SIGMAR1
4 Cross references
204 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSORLG00000014357
Gene Symbol: SMO
4 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha

Ensembl ID : ENSORLG00000011677
Gene Symbol: LOC101159774
4 Cross references
248 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha B

Ensembl ID : ENSORLG00000003273
Gene Symbol: LOC101167997
3 Cross references
256 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit B

Ensembl ID : ENSORLG00000019133
Gene Symbol: SCN8AB
3 Cross references
216 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSORLG00000006930
Gene Symbol: SCN8A
4 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).